Literature DB >> 17142251

Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo.

Eugenia Trushina1, Raman Deep Singh, Roy B Dyer, Sheng Cao, Vijay H Shah, Robert G Parton, Richard E Pagano, Cynthia T McMurray.   

Abstract

We show that the mutant Huntington's disease (HD) protein (mhtt) specifically inhibits endocytosis in primary striatal neurons. Unexpectedly, mhtt does not inhibit clathrin-dependent endocytosis as was anticipated based on known interacting partners. Instead, inhibition occurs through a non-clathrin, caveolar-related pathway. Expression of mhtt inhibited internalization of BODIPY-lactosylceramide (LacCer), which is internalized by a caveolar-related mechanism. In contrast, endocytosis of Alexa Fluor 594-transferrin (Tfn) and epidermal growth factor, internalized through clathrin pathway, was unaffected by mhtt expression. Caveolin-1 (cav1), the major structural protein of caveolae binds cholesterol and is responsible for its trafficking inside cells. Mhtt interacts with cav-1 and caused a striking accumulation of intracellular cholesterol. Cholesterol accumulated in cultured neurons expressing mhtt in vitro and in brains of mhtt-expressing animals in vivo, and was observed after induction of mhtt expression in PC-12 cell lines. The accumulation occurred only when mhtt and cav1 were simultaneously expressed in cells. Knockdown of cav1 in mhtt-expressing neurons blocked cholesterol accumulation and restored LacCer endocytosis. Thus, mhtt and cav1 functionally interact to cause both cellular defects. These data provide the first direct link between mhtt and caveolar-related endocytosis and also suggest a possible mechanism for HD neurotoxicity where cholesterol homeostasis is perturbed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142251     DOI: 10.1093/hmg/ddl434

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

2.  SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis.

Authors:  Ruth Luthi-Carter; David M Taylor; Judit Pallos; Emmanuel Lambert; Allison Amore; Alex Parker; Hilary Moffitt; Donna L Smith; Heike Runne; Ozgun Gokce; Alexandre Kuhn; Zhongmin Xiang; Michele M Maxwell; Steven A Reeves; Gillian P Bates; Christian Neri; Leslie M Thompson; J Lawrence Marsh; Aleksey G Kazantsev
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

3.  Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo.

Authors:  Eugenia Trushina; Christie A Canaria; Do-Yup Lee; Cynthia T McMurray
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

Review 4.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

5.  Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity.

Authors:  Xueyi Li; Clive Standley; Ellen Sapp; Antonio Valencia; Zheng-Hong Qin; Kimberly B Kegel; Jennifer Yoder; Laryssa A Comer-Tierney; Miguel Esteves; Kathryn Chase; Jonathan Alexander; Nicholas Masso; Lindsay Sobin; Karl Bellve; Richard Tuft; Lawrence Lifshitz; Kevin Fogarty; Neil Aronin; Marian DiFiglia
Journal:  Mol Cell Biol       Date:  2009-09-14       Impact factor: 4.272

6.  A large scale Huntingtin protein interaction network implicates Rho GTPase signaling pathways in Huntington disease.

Authors:  Cendrine Tourette; Biao Li; Russell Bell; Shannon O'Hare; Linda S Kaltenbach; Sean D Mooney; Robert E Hughes
Journal:  J Biol Chem       Date:  2014-01-09       Impact factor: 5.157

Review 7.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

8.  Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes.

Authors:  Xiang Gao; Warren A Campbell; Maxmore Chaibva; Pranav Jain; Ashley E Leslie; Shelli L Frey; Justin Legleiter
Journal:  Biochemistry       Date:  2015-12-22       Impact factor: 3.162

9.  Expression analysis of novel striatal-enriched genes in Huntington disease.

Authors:  Gelareh Mazarei; Scott J Neal; Kristina Becanovic; Ruth Luthi-Carter; Elizabeth M Simpson; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2009-11-23       Impact factor: 6.150

10.  Tricyclic pyrone compounds prevent aggregation and reverse cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons.

Authors:  Eugenia Trushina; Sandeep Rana; Cynthia T McMurray; Duy H Hua
Journal:  BMC Neurosci       Date:  2009-07-08       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.